Skip to main content
Clinical Trials/NCT05072288
NCT05072288
Active, not recruiting
Not Applicable

A Remote Physical Activity Program Via the PACE Tool to Counter the Physical Impairments, Accentuated by the Pandemic, in the Population Suffering from Type 1 Myotonic Dystrophy

Université du Québec à Chicoutimi2 sites in 1 country40 target enrollmentAugust 11, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myotonic Dystrophy Type 1 (DM1)
Sponsor
Université du Québec à Chicoutimi
Enrollment
40
Locations
2
Primary Endpoint
Change in Functional capacity from baseline to week 12
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.

Registry
clinicaltrials.gov
Start Date
August 11, 2021
End Date
December 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • DM1 diagnosis must be confirmed by genetic analysis (juvenile, adults or late-onset phenotypes);
  • Aged between 18 and 60 years old;
  • Be able to do exercise;
  • Subjects must be able to give their consent freely and voluntarily.

Exclusion Criteria

  • Patients who already train (\>3 times per week or \>150min/week);
  • Don't speak french or english;
  • Are not able to do exercise (even in sitting position);

Outcomes

Primary Outcomes

Change in Functional capacity from baseline to week 12

Time Frame: Week 12

Short physical performance battery Functional reach test

Change in the Level of physical activity from baseline to week 12

Time Frame: Week 12

Rapid Assessment of physical Activity \& International Physical Activity Questionnaires

Feasability/acceptability of the program and Satisfaction

Time Frame: Week 12

Number of sessions completed/planned Likert System Usability Scale.

Secondary Outcomes

  • Changes in the score of the Fatigue and Daytime Sleepiness Scale from baseline to week 12(Week 12)
  • Changes in the Marin apathy scale from baseline to week 12(Week 12)

Study Sites (2)

Loading locations...

Similar Trials